Advanced searches left 3/3

Type 2 Diabetes - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 09 June 2022

* If you want to update the article please login/register

Three months of combination therapy with nano‐curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double‐blinded, placebo‐controlled clinical trial

"Diabetes is one of the most common chronic diseases worldwide. " Diabetes-related diabetes and acute coronary syndrome in diabetic patients have been a primary factor in the development and progression of atherosclerosis and acute coronary syndrome. Therefore, we wanted to investigate the effects of nanou2010curcumin on cardiovascular risk factors in type 2 diabetic patients with mild to moderate coronary artery disease. In addition, the mean percentage of change in the hsu2010CRP and LipoPr levels in the nanou2010curcumin group was significantly reduced in the nano-u2010curcumin group relative to the placebo group. Nanou2010Crop significantly increased the number of patients with mild to moderate hsu2010CRP level category and dramatically reduced the number of patients with severe hsu2010CRP status category in comparison to the placebo group, although perhaps not related to the placebo group. Nanou2010curcumin can help reduce atherosclerosis progression, as well as attenuating hsu2010CRP levels as an inflammation marker, and diabetic heart patients' succedent cardiovascular events.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/biof.1874


EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients

"We wanted to determine EndoBarrier's safety and effectiveness in patients with suboptimally controlled diabetes who have suboptimally"u2010 controlled diabesity. Weight loss from 139. 0 to 58. 6 kg in 0. 001, a systolic BP from 78. 1 mmHg to 126. 6 percent (p 0. 051) decreased from 59. 4 u00b1 15. 6kg to 202. 8 mol/mol p 0. 051, and serum alanine 1. 0Mmol/mol from 78. 1 u00b1 16. 0 to 58. 8 kgs p 0. 01 b1 8. 8 0 p b1 u00b1 2. 8 p u00b1 581 u00b1 p tu00b1 p 0. 01 p 0 to 0. 6 u00b1 1. 0 b1 p a1 1. 0 p u00b1 tu00b1 b1 1. 0 p u00b1 1. 0 3. 2 p 1. 0 1. 2 1. 0 tu00b1 0. 051 0. 4 b1 0. 9 Patients of 42 of 42. 2% insulin-treated patients were given insulin. Sixteen of 901 percent patients required EndoBarrier surgery: five for gastrointestinal haemorrhage, two for liver absces, two for non-u2010hepatic intrau2010abdominal absces, five for urinary abnormalities, and five for digestive disorders.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/pdi.2393


Combination therapy of bioactive compounds with acarbose: A proposal to control hyperglycemia in type 2 diabetes

"Type 2 diabetes is a chronic metabolic disease with a major effect on public health and social stability. " However, ACB has poor adherence to diabetes medication among diabetic patients due to its side effects. Consequently, treating T2D requires minimizing the side effects caused by ACB without compromiseing its efficacy. This report examines the combined therapy of BC with ACB in inhibiting AMY and GLU in T2D as a way to prevent hyperglycemia in T2D. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14268


Type 2 Diabetes mellitus treatment intensification and deintensification in primary care: a retrospective cohort study

"The prevalence of type 2 diabetes is on the rise around the world, indicating a significant clinical and public health burden. " Existing evidence shows that optimizing diabetes management regimens can reduce the risk of morbidity and disability. This retrospective observational cohort study sought to identify factors associated with treatment initiation and deintensification in type 2 diabetes patients with type 2 diabetes and evaluation of therapeutic strategies on clinical outcomes. Between January 2016 and March 2020, 183 patients were enrolled in a primary care Diabetes Medication Adherence Clinic program in Malaysia between 1 January 2016 and March 2020. Patients' medicine regimens were altered, of which 27. 4% of patients' medications were reformulated, 8. 6% of patients' medications were deintensified, and 13. 7% of patients' medications were increased and deintensified, of which 13. 7% of patients' were randomized and deintensified. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jppr.1812


Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes—A randomized placebo‐controlled crossover trial

"We investigated the metabolic consequences of long-term melatonin therapy in patients with type 2 diabetes, including determinations of insulin sensitivity and glucose-u2010stimulated insulin secretion. " Seventeen male sufferers with type 2 diabetes completed three months of daily melatonin therapy 1 h before bedtime and three months of placebo therapy 1 h before bedtime. In conclusion, melatonin therapy of male patients with type 2 diabetes for three months decreased insulin sensitivity by 12%. In situations where the benefits outweigh the potential negative effect on insulin sensitivity, clinical use of melatonin treatment in 10 mg should be reserved.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/jpi.12809

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions